SK Bioscience applies for conditional approval of Skycovion from UK MHRA
[Asia Economy Reporter Minji Lee] SK Bioscience announced on the 29th that it has applied for conditional approval of the COVID-19 vaccine Skycovion from the UK MHRA.
Hot Picks Today
If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- Trump: "Talks in Final Stages," Iran Reviewing U.S. Proposal... Oil Prices Plunge 5% (Comprehensive)
- Room Prices Soar from 60,000 to 760,000 Won and Sudden Cancellations: "We Won't Even Buy Water in Busan" — BTS Fans Outraged
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The company stated, "High neutralizing antibodies that can contribute to the prevention of COVID-19 were induced after the primary vaccination with Skycovion, and the safety profile was also at an acceptable level," adding, "We expect to proceed with supply in the UK and expand approval countries after obtaining approval from the UK MHRA."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing 90 Degrees These Days Actually Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
